Global drug pricing is a major source of barriers to access to medicines. It also affects the incentives of manufacturers to invest in new product development and innovation and can drive down patient access to life-saving drugs.
The United States spends over twice as much per person on prescription medications as most other OECD countries. This cost-sharing is passed on to Americans through higher insurance premiums and taxpayer-funded public programs.
Cost-Effectiveness
In the United States, prescription drug prices are typically 2 to 4 times higher than in comparable industrialized countries. This difference is most pronounced in oncology and has implications for patients with cancer, especially those uninsured or with limited coverage.
There are several important reasons for this gap in prices. First, price of prescription drugs in the United States is primarily defined by what pharmaceutical companies want to charge when a new drug is launched rather than by its clinical benefit. This practice is also driven by confidential rebates between buyers and drug companies, making it difficult to compare list prices to what they cost.
Second, many drugs have been approved through the FDA’s Accelerated Approval pathway but offer little to no value for patients compared to existing drugs. This is particularly true of me-too drugs, which are late entries into a therapeutic class with several existing drugs and generally do not benefit patients more than those already on the market.
Third, many medicines have been developed with very high research costs but are not expected to improve patient outcomes significantly. This is especially the case in rare diseases, where research funding has yet to be fully utilized, or researchers are unsure whether their work will result in new effective, affordable medicines for patients.
Fourth, there are a variety of pricing policies in place to control the cost of innovative products. Some focus on regulating the price of new drugs approved for use in a specific therapeutic area. These policies ensure a drug’s price does not disproportionately harm low-income or vulnerable populations.
Fifth, some governments use value-based pricing to lower drug prices while promoting innovation.
Accessibility
Global drug pricing is a complex issue. It affects many stakeholders, including pharmaceutical companies, payers, and consumers. Ultimately, it affects access to medicines, especially new, expensive drugs.
On average, brand-name drug prices in the United States are nearly 2 to 4 times higher than those in comparable industrialized countries. This contrasts starkly with most other countries, where brand-name drugs are regulated after launch by regulatory authorities and are then negotiated based on the clinical benefits they provide to patients.
Some countries have introduced or are considering regulations that could reduce the gap between list and negotiated prices, a practice known as international reference pricing. Although this practice has successfully controlled spending in some cases, it has challenges.
One of the major concerns associated with international reference pricing is that it could lead to a shift in pharmaceutical development. Drug manufacturers may focus more on developing new drugs for less costly markets with less demand. The resulting lack of competition will have an adverse impact on the availability and affordability of these medicines.
Social Impact
In many ways, global drug pricing affects access to medications. In the United States, for example, many pharmaceuticals used to treat serious diseases are priced at levels that prevent those with low incomes or health insurance from accessing them. This dilemma is exacerbated by many new medications not being priced with therapeutic value in mind.
Governments must ensure these drugs are fairly priced to increase patient access to life-saving medications. This is an important goal for all nations, especially in lower-income countries.
Governments must be able to negotiate prices for new pharmaceuticals to ensure that a fair price is paid. These negotiations can be carried out in a variety of ways. One alternative is to use International Reference Prices, the prices other countries pay for comparable products. These prices are frequently utilized as a negotiating point with the pharmaceutical sector.
Governments need to ensure that a fair value is paid for new drugs to prevent the abuse of monopoly periods. Three mechanisms can achieve this:
- Government negotiations for brand-name drugs that face little or no competition.
- The use of International Reference Prices or other measures as a benchmark for U.S. prices.
- An inflation rebate.
Innovation
Drug innovation and access to life-saving medicines are important global issues. As the population ages and chronic disease continues to rise, new treatments and cures are needed more than ever. However, the cost of innovative research and development can be prohibitive.
This has led to several policy proposals and regulations limiting drug pricing. These include international reference pricing, which cites prices from other countries to regulate drug prices in the U.S., and value-based contracting, in which biopharmaceutical companies commit to providing lower price discounts when certain clinical outcomes are met, or economic returns are achieved.
While these policies aim to control drug spending, they also pose significant challenges to the innovation potential of biopharmaceutical companies. This is particularly true regarding drugs that tackle complex social problems such as HIV, diabetes, and tuberculosis.
These goods have great social value and can help individuals and families improve their health, but they often have lower financial returns than development expenditures. This tendency has fueled efforts to create medications through a public-private cooperation.
As these initiatives take effect, biopharmaceutical manufacturers must establish and deploy innovative financial models and data strategies that can effectively navigate the global market. Additionally, they will need to adopt organizational changes that can effectively manage the cost of development and product launch.
